Shenzhen Hepalink Pharmaceutical Group Co Ltd (SHEZF) Gagner

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 1,926 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The firm operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The firm conducts its business in the domestic and overseas markets.